IL123998A - Conjugates of bile salts and pharmaceutical preparations containing them - Google Patents
Conjugates of bile salts and pharmaceutical preparations containing themInfo
- Publication number
- IL123998A IL123998A IL12399898A IL12399898A IL123998A IL 123998 A IL123998 A IL 123998A IL 12399898 A IL12399898 A IL 12399898A IL 12399898 A IL12399898 A IL 12399898A IL 123998 A IL123998 A IL 123998A
- Authority
- IL
- Israel
- Prior art keywords
- acid
- bile
- fatty acid
- dihydroxy
- oic
- Prior art date
Links
- 239000003833 bile salt Substances 0.000 title claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 10
- 239000003613 bile acid Substances 0.000 claims abstract description 34
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 34
- 229930195729 fatty acid Natural products 0.000 claims abstract description 34
- 239000000194 fatty acid Substances 0.000 claims abstract description 34
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims abstract description 24
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 21
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 5
- 150000001413 amino acids Chemical class 0.000 claims abstract description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 64
- 210000000941 bile Anatomy 0.000 claims description 56
- 235000012000 cholesterol Nutrition 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 19
- 201000001883 cholelithiasis Diseases 0.000 claims description 19
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 11
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 9
- 238000004090 dissolution Methods 0.000 claims description 8
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 7
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 7
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 7
- 239000004380 Cholic acid Substances 0.000 claims description 7
- 235000021355 Stearic acid Nutrition 0.000 claims description 7
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 7
- 229960002471 cholic acid Drugs 0.000 claims description 7
- 235000019416 cholic acid Nutrition 0.000 claims description 7
- 230000021615 conjugation Effects 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 239000008117 stearic acid Substances 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 4
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 4
- 229960001661 ursodiol Drugs 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 3
- 229960001091 chenodeoxycholic acid Drugs 0.000 claims description 3
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims description 3
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229960003964 deoxycholic acid Drugs 0.000 claims description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 90
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 67
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 47
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 229940093499 ethyl acetate Drugs 0.000 description 30
- 235000019439 ethyl acetate Nutrition 0.000 description 30
- 150000004702 methyl esters Chemical class 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 20
- 150000003904 phospholipids Chemical class 0.000 description 18
- 238000003756 stirring Methods 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000013078 crystal Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 229940099352 cholate Drugs 0.000 description 11
- 238000002425 crystallisation Methods 0.000 description 11
- 230000008025 crystallization Effects 0.000 description 11
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 229940086542 triethylamine Drugs 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000012223 aqueous fraction Substances 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 101150041968 CDC13 gene Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- -1 bile acid fatty acid Chemical class 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 5
- 235000021314 Palmitic acid Nutrition 0.000 description 5
- 230000010235 enterohepatic circulation Effects 0.000 description 5
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 5
- 230000006911 nucleation Effects 0.000 description 5
- 238000010899 nucleation Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229940093761 bile salts Drugs 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 210000000232 gallbladder Anatomy 0.000 description 4
- 208000001130 gallstones Diseases 0.000 description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 230000007928 solubilization Effects 0.000 description 4
- 238000005063 solubilization Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000001839 systemic circulation Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003858 bile acid conjugate Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 2
- WTBAHSZERDXKKZ-UHFFFAOYSA-N octadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCCCC(Cl)=O WTBAHSZERDXKKZ-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- GTRMJEVFVTWDIU-KPNWGBFJSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol;hydrate Chemical compound O.C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 GTRMJEVFVTWDIU-KPNWGBFJSA-N 0.000 description 1
- IFABLCIRROMTAN-MDZDMXLPSA-N (e)-1-chlorooctadec-9-ene Chemical compound CCCCCCCC\C=C\CCCCCCCCCl IFABLCIRROMTAN-MDZDMXLPSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- YAYNEUUHHLGGAH-UHFFFAOYSA-N 1-chlorododecane Chemical compound CCCCCCCCCCCCCl YAYNEUUHHLGGAH-UHFFFAOYSA-N 0.000 description 1
- GIUTUZDGHNZVIA-UHFFFAOYSA-N 2-(ethylamino)acetic acid;hydrochloride Chemical compound Cl.CCNCC(O)=O GIUTUZDGHNZVIA-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QHOINBKBMJLHPY-UHFFFAOYSA-N 2-chloroethyl formate Chemical compound ClCCOC=O QHOINBKBMJLHPY-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- UNSAJINGUOTTRA-UHFFFAOYSA-N 3-(3-bromophenyl)prop-2-yn-1-ol Chemical compound OCC#CC1=CC=CC(Br)=C1 UNSAJINGUOTTRA-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- QTHQYNCAWSGBCE-UHFFFAOYSA-N docosanoyl chloride Chemical compound CCCCCCCCCCCCCCCCCCCCCC(Cl)=O QTHQYNCAWSGBCE-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 description 1
- YWGHUJQYGPDNKT-UHFFFAOYSA-N hexanoyl chloride Chemical compound CCCCCC(Cl)=O YWGHUJQYGPDNKT-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- BXZBGYJQEFZICM-UHFFFAOYSA-N icosanoyl chloride Chemical compound CCCCCCCCCCCCCCCCCCCC(Cl)=O BXZBGYJQEFZICM-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- WVJVHUWVQNLPCR-UHFFFAOYSA-N octadecanoyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCC WVJVHUWVQNLPCR-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001907 polarising light microscopy Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 229940014499 ursodeoxycholate Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Fats And Perfumes (AREA)
Priority Applications (28)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12399898A IL123998A (en) | 1998-04-08 | 1998-04-08 | Conjugates of bile salts and pharmaceutical preparations containing them |
| CNB998049034A CN100386339C (zh) | 1998-04-08 | 1999-03-25 | 胆汁酸和胆汁酸衍生物的脂肪酸衍生物 |
| CZ20003625A CZ300824B6 (cs) | 1998-04-08 | 1999-03-25 | Konjugáty žlucové kyseliny nebo žlucové soli s mastnou kyselinou a farmaceutický prostredek je obsahující |
| BRPI9909908A BRPI9909908B8 (pt) | 1998-04-08 | 1999-03-25 | conjugados de ácido graxo de sal ou ácido biliar, composição farmacêutica compreendendo os mesmos e seus usos |
| JP2000543488A JP5031942B2 (ja) | 1998-04-08 | 1999-03-25 | 胆汁酸および胆汁酸誘導体の脂肪酸誘導体 |
| NZ507309A NZ507309A (en) | 1998-04-08 | 1999-03-25 | Fatty acid derivatives of bile acids and bile acid derivatives |
| AU30515/99A AU742944B2 (en) | 1998-04-08 | 1999-03-25 | Fatty acid derivatives of bile acids and bile acid derivatives |
| EP99912026A EP1071702B1 (en) | 1998-04-08 | 1999-03-25 | Fatty acid derivatives of bile acids and bile acid derivatives |
| PT99912026T PT1071702E (pt) | 1998-04-08 | 1999-03-25 | Derivados de acidos gordos de acidos biliares e derivados de acidos biliares |
| HU0101653A HU229513B1 (en) | 1998-04-08 | 1999-03-25 | Fatty acid derivatives of bile acids and bile acid derivatives |
| DK99912026T DK1071702T3 (da) | 1998-04-08 | 1999-03-25 | Fedtsyrederivater af galdesyre og galdesyrederivater |
| ES99912026T ES2183526T3 (es) | 1998-04-08 | 1999-03-25 | Derivados de acidos grasos de acidos biliares y derivados del acido biliar. |
| DE69902647T DE69902647T2 (de) | 1998-04-08 | 1999-03-25 | Fettsäurederivate von gallensäure und gallensäurederivaten |
| KR1020007010903A KR100615560B1 (ko) | 1998-04-08 | 1999-03-25 | 담즙산 및 담즙산 유도체의 지방산 유도체 |
| UA2000095546A UA70318C2 (uk) | 1998-04-08 | 1999-03-25 | Жирнокислотні похідні жовчних кислот та похідних жовчної кислоти, фармацевтичний препарат для розчинення холестеринових жовчних каменів і запобігання атеросклерозу, спосіб лікування (варіанти) |
| SI9930142T SI1071702T1 (en) | 1998-04-08 | 1999-03-25 | Fatty acid derivatives of bile acids and bile acid derivatives |
| CA002325933A CA2325933C (en) | 1998-04-08 | 1999-03-25 | Fatty acid derivatives of bile acids and bile acid derivatives |
| PCT/IL1999/000173 WO1999052932A1 (en) | 1998-04-08 | 1999-03-25 | Fatty acid derivatives of bile acids and bile acid derivatives |
| PL343360A PL199271B1 (pl) | 1998-04-08 | 1999-03-25 | Koniugaty kwasu żółciowego lub soli żółciowej z kwasem tłuszczowym, zawierająca je kompozycja farmaceutyczna oraz ich zastosowanie |
| AT99912026T ATE222923T1 (de) | 1998-04-08 | 1999-03-25 | Fettsäurederivate von gallensäure und gallensäurederivaten |
| EA200000888A EA003392B1 (ru) | 1998-04-08 | 1999-03-25 | Производные желчных кислот |
| IDW20001998A ID26042A (id) | 1998-04-08 | 1999-03-25 | Turunan-turunan asam lemak dari asam-asam empedu dan asam empedu |
| TR2000/02876T TR200002876T2 (tr) | 1998-04-08 | 1999-03-25 | Safra asit türevlerinin ve safra asitlerinin yağ asit türevleri |
| US09/675,656 US6395722B1 (en) | 1998-04-08 | 2000-09-29 | Fatty acid derivatives of bile acids and bile acid derivatives |
| NO20004998A NO316875B1 (no) | 1998-04-08 | 2000-10-04 | Fettsyrederivater av gallesyrer og gallesyrederivater |
| US09/693,928 US6384024B1 (en) | 1998-04-08 | 2000-10-23 | Bile salt conjugates |
| IL142650A IL142650A (en) | 1998-04-08 | 2001-04-17 | Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes |
| US10/078,671 US6589946B2 (en) | 1998-04-08 | 2002-02-21 | Bile salt conjugates |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12399898A IL123998A (en) | 1998-04-08 | 1998-04-08 | Conjugates of bile salts and pharmaceutical preparations containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL123998A true IL123998A (en) | 2004-09-27 |
Family
ID=11071405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12399898A IL123998A (en) | 1998-04-08 | 1998-04-08 | Conjugates of bile salts and pharmaceutical preparations containing them |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US6395722B1 (pt) |
| EP (1) | EP1071702B1 (pt) |
| JP (1) | JP5031942B2 (pt) |
| KR (1) | KR100615560B1 (pt) |
| CN (1) | CN100386339C (pt) |
| AT (1) | ATE222923T1 (pt) |
| AU (1) | AU742944B2 (pt) |
| BR (1) | BRPI9909908B8 (pt) |
| CA (1) | CA2325933C (pt) |
| CZ (1) | CZ300824B6 (pt) |
| DE (1) | DE69902647T2 (pt) |
| DK (1) | DK1071702T3 (pt) |
| EA (1) | EA003392B1 (pt) |
| ES (1) | ES2183526T3 (pt) |
| HU (1) | HU229513B1 (pt) |
| ID (1) | ID26042A (pt) |
| IL (1) | IL123998A (pt) |
| NO (1) | NO316875B1 (pt) |
| NZ (1) | NZ507309A (pt) |
| PL (1) | PL199271B1 (pt) |
| PT (1) | PT1071702E (pt) |
| SI (1) | SI1071702T1 (pt) |
| TR (1) | TR200002876T2 (pt) |
| UA (1) | UA70318C2 (pt) |
| WO (1) | WO1999052932A1 (pt) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015186126A1 (en) * | 2014-06-01 | 2015-12-10 | Galmed Research And Development Ltd. | Fatty acid bile acid conjugates for treatment of lipodystrophy |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL123998A (en) * | 1998-04-08 | 2004-09-27 | Galmed Int Ltd | Conjugates of bile salts and pharmaceutical preparations containing them |
| IL142650A (en) * | 1998-04-08 | 2007-06-03 | Galmed Int Ltd | Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes |
| US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
| US8975246B2 (en) | 2001-04-17 | 2015-03-10 | Galmed Research And Development Ltd. | Bile acid or bile salt fatty acid conjugates |
| US7053076B2 (en) | 2001-08-29 | 2006-05-30 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| ITMI20021025A1 (it) * | 2002-05-14 | 2003-11-14 | Nicox Sa | Farmaci per il trattamento acuto di disfunzioni del circolo venoso epatico e portale |
| US20080026077A1 (en) * | 2002-11-12 | 2008-01-31 | John Hilfinger | Methods and compositions of gene delivery agents for systemic and local therapy |
| US7906137B2 (en) * | 2004-05-21 | 2011-03-15 | Mediplex Corporation, Korea | Delivery agents for enhancing mucosal absorption of therapeutic agents |
| WO2007084549A2 (en) * | 2006-01-20 | 2007-07-26 | Filiberto Zadini | Drug-eluting stent with atherosclerotic plaques dissolving pharmacological preparation |
| US8304383B2 (en) | 2005-11-22 | 2012-11-06 | Atheronova Operations, Inc. | Dissolution of arterial plaque |
| US20090035348A1 (en) * | 2005-11-22 | 2009-02-05 | Z & Z Medical Holdings, Inc. | Dissolution of arterial plaque |
| US20070212470A1 (en) * | 2006-03-13 | 2007-09-13 | Nutracea | Therapeutic uses of an anti-cancer composition derived from rice bran |
| US20080038385A1 (en) * | 2006-03-13 | 2008-02-14 | Nutracea | Therapeutic uses of an anti-cancer composition derived from rice bran |
| US20090305943A1 (en) * | 2006-07-18 | 2009-12-10 | Sven Siegel | Cyclodextrin blends with crystal growth inhibitors |
| AU2008242583B2 (en) | 2007-04-23 | 2013-10-10 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of RNA interference agents |
| WO2008144458A1 (en) * | 2007-05-15 | 2008-11-27 | Z & Z Medical Holdings, Inc. | Dissolution of arterial cholesterol plaques by pharmacologically induced elevation of endogenous bile salts |
| PT2182954T (pt) * | 2007-07-25 | 2019-02-06 | Univ Graz Medizinische | Utilização de ácidos nor-biliares no tratamento de arteriosclerose |
| CN101367859B (zh) * | 2007-08-17 | 2011-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 脂肪酸胆汁酸偶合物及其医药用途 |
| CZ301037B6 (cs) * | 2007-09-06 | 2009-10-21 | Vysoká škola chemicko-technologická v Praze | Amidové konjugáty steroidních a žlucových kyselin s D-glukosaminem a zpusob jejich prípravy |
| CA2708171C (en) | 2007-12-04 | 2018-02-27 | Alnylam Pharmaceuticals, Inc. | Folate conjugates |
| CA2910760C (en) | 2007-12-04 | 2019-07-09 | Muthiah Manoharan | Targeting lipids |
| US20100021538A1 (en) * | 2008-02-29 | 2010-01-28 | Youngro Byun | Pharmaceutical compositions containing heparin derivatives |
| WO2009126933A2 (en) | 2008-04-11 | 2009-10-15 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| EP2367839A4 (en) * | 2008-11-03 | 2012-07-04 | Univ Tufts | METHODS AND COMPOSITIONS FOR PREVENTING GERMINATION AND EXCROIDANCE OF C. DIFFICILE SPORES |
| EP2391370B1 (en) * | 2009-02-02 | 2015-06-03 | Galmed Research and Development Ltd. | Methods and compositions for treating alzheimer's disease |
| GB2480632A (en) | 2010-05-25 | 2011-11-30 | Kythera Biopharmaceuticals Inc | Preparation of 12-keto and 12-alpha-hydroxy steroids |
| CN102115486B (zh) * | 2009-12-30 | 2015-06-03 | 上海特化医药科技有限公司 | 一种3-β-花生酰胺基-7α,12α,5β-胆烷-24-羧酸的制备方法 |
| TWI572616B (zh) * | 2011-06-16 | 2017-03-01 | 凱瑟拉生物製藥有限公司 | 去氧膽酸之組成物及用途及其相關方法 |
| JP2016527307A (ja) * | 2013-08-08 | 2016-09-08 | ガルデルム セラピューティクス リミテッド | 胆汁酸−脂肪酸抱合体を含む抗座瘡組成物 |
| PT3077047T (pt) * | 2013-12-04 | 2019-07-11 | Galmed Res & Development Ltd | Sais de aramchol |
| US11571431B2 (en) | 2013-12-04 | 2023-02-07 | Galmed Research And Development Ltd | Aramchol salts |
| JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
| US10849911B2 (en) | 2015-06-10 | 2020-12-01 | Galmed Research And Development Ltd. | Low dose compositions of Aramachol salts |
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
| CN106496300B (zh) * | 2016-10-19 | 2018-05-18 | 上海博志研新药物技术有限公司 | 花生胆酸及其中间体的制备方法 |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| WO2018087600A1 (en) * | 2016-11-10 | 2018-05-17 | Galmed Research And Development Ltd. | Inhibition of fibrosis in non-alcoholic fatty liver disease patients |
| US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
| WO2018223836A1 (zh) | 2017-06-07 | 2018-12-13 | 苏州科睿思制药有限公司 | 一种脂肪酸胆汁酸偶合物的晶型及其制备方法和用途 |
| US11492623B2 (en) | 2018-08-13 | 2022-11-08 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof |
| IT202000000328A1 (it) | 2020-01-10 | 2021-07-10 | Ice S P A | Metodo di preparazione dell'aramchol |
| CN114524857B (zh) * | 2022-02-22 | 2023-06-30 | 中国科学院微生物研究所 | 胆酸衍生物及其应用 |
| CN116687850A (zh) | 2022-02-24 | 2023-09-05 | 甘莱制药有限公司 | 包含环状膦酸酯化合物的药物组合物及其制备方法与用途 |
| WO2023227723A1 (en) * | 2022-05-26 | 2023-11-30 | Pharmazell Gmbh | An improved process for the preparation of aramchol and salts thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3856953A (en) * | 1973-05-15 | 1974-12-24 | Intellectual Property Dev Corp | Method of treating fatty liver |
| IT1167479B (it) * | 1981-07-24 | 1987-05-13 | Carlo Scolastico | Derivati dell'acido chenodesossicolico |
| IT1167478B (it) * | 1981-07-24 | 1987-05-13 | Carlo Scolastico | Derivati dell'acido ursodesossicolico |
| DE3930696A1 (de) * | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
| IL123998A (en) * | 1998-04-08 | 2004-09-27 | Galmed Int Ltd | Conjugates of bile salts and pharmaceutical preparations containing them |
| DE19824123A1 (de) * | 1998-05-29 | 1999-12-02 | Hoechst Marion Roussel De Gmbh | Gallensäurederivat, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
-
1998
- 1998-04-08 IL IL12399898A patent/IL123998A/en not_active IP Right Cessation
-
1999
- 1999-03-25 PT PT99912026T patent/PT1071702E/pt unknown
- 1999-03-25 TR TR2000/02876T patent/TR200002876T2/xx unknown
- 1999-03-25 EP EP99912026A patent/EP1071702B1/en not_active Expired - Lifetime
- 1999-03-25 DE DE69902647T patent/DE69902647T2/de not_active Expired - Lifetime
- 1999-03-25 WO PCT/IL1999/000173 patent/WO1999052932A1/en active IP Right Grant
- 1999-03-25 HU HU0101653A patent/HU229513B1/hu unknown
- 1999-03-25 SI SI9930142T patent/SI1071702T1/xx unknown
- 1999-03-25 CN CNB998049034A patent/CN100386339C/zh not_active Expired - Lifetime
- 1999-03-25 ID IDW20001998A patent/ID26042A/id unknown
- 1999-03-25 CZ CZ20003625A patent/CZ300824B6/cs not_active IP Right Cessation
- 1999-03-25 BR BRPI9909908A patent/BRPI9909908B8/pt not_active IP Right Cessation
- 1999-03-25 ES ES99912026T patent/ES2183526T3/es not_active Expired - Lifetime
- 1999-03-25 AT AT99912026T patent/ATE222923T1/de active
- 1999-03-25 DK DK99912026T patent/DK1071702T3/da active
- 1999-03-25 NZ NZ507309A patent/NZ507309A/xx not_active IP Right Cessation
- 1999-03-25 JP JP2000543488A patent/JP5031942B2/ja not_active Expired - Lifetime
- 1999-03-25 PL PL343360A patent/PL199271B1/pl unknown
- 1999-03-25 EA EA200000888A patent/EA003392B1/ru not_active IP Right Cessation
- 1999-03-25 UA UA2000095546A patent/UA70318C2/uk unknown
- 1999-03-25 CA CA002325933A patent/CA2325933C/en not_active Expired - Lifetime
- 1999-03-25 AU AU30515/99A patent/AU742944B2/en not_active Expired
- 1999-03-25 KR KR1020007010903A patent/KR100615560B1/ko not_active IP Right Cessation
-
2000
- 2000-09-29 US US09/675,656 patent/US6395722B1/en not_active Expired - Lifetime
- 2000-10-04 NO NO20004998A patent/NO316875B1/no not_active IP Right Cessation
- 2000-10-23 US US09/693,928 patent/US6384024B1/en not_active Expired - Lifetime
-
2002
- 2002-02-21 US US10/078,671 patent/US6589946B2/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015186126A1 (en) * | 2014-06-01 | 2015-12-10 | Galmed Research And Development Ltd. | Fatty acid bile acid conjugates for treatment of lipodystrophy |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL123998A (en) | Conjugates of bile salts and pharmaceutical preparations containing them | |
| US5571795A (en) | Derivative-compound-conjugates and pharmaceutical compositions comprising same | |
| US5264424A (en) | Modified gangliosides and the functional derivatives thereof | |
| US5627270A (en) | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same | |
| US5583239A (en) | Antimicrobial sterol conjugates | |
| US5693769A (en) | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same | |
| EP0676410B1 (en) | Bile acids derivatives useful in the therapy of the biliary calculosis from cholesterol and of the pathologies caused by cholestasis | |
| Parmentier et al. | Synthesis and characteristics of the specific monosulfates of chenodeoxycholate, deoxycholate and their taurine or glycine conjugates | |
| US5455268A (en) | Esculetin derivatives and pharmaceutical composition | |
| US3867413A (en) | Fusidic acid conjugates | |
| AU696090B2 (en) | New glucocorticoids | |
| Roda et al. | New 6-substituted bile acids: physico-chemical and biological properties of 6 alpha-methyl ursodeoxycholic acid and 6 alpha-methyl-7-epicholic acid. | |
| US5677285A (en) | Derivatives of neuraminic acid | |
| MXPA00009863A (en) | Fatty acid derivatives of bile acids and bile acid derivatives | |
| EP0527832A1 (en) | Anti-fungal bile acid derivatives | |
| US3708510A (en) | Amides of cholanic acid,cholenic acid,and choladienic acid | |
| EP0092073A1 (en) | Magnesium salt of chenodeoxycholic acid and ursodeoxycholic acid, the process for its preparation, and therapeutic compositions which contain it as active principle | |
| Roda et al. | New 6-substituted bile acids: physico-chemical and biological properties of 6~ methyl ursodeoxycholic acid and 6a-methylg% epicholic acid | |
| JPH06192266A (ja) | 抗生物質ｎｋ８６−０２７９−ｉの新規誘導体、その製造法及び用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Corrigendum |
Free format text: JOURNAL 7/04 P. 2594 PATENT APPLICATION NO. 123998 IN THE ABSTRACT, REPLACE... 18-22... BY... 6-22... |
|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |